Citi 2016 Global Healthcare Conference › ... › Citi-Conference_FINAL.pdfCiti 2016 Global...
Transcript of Citi 2016 Global Healthcare Conference › ... › Citi-Conference_FINAL.pdfCiti 2016 Global...
Citi 2016 Global Healthcare Conference Mikael Dolsten, M.D., Ph.D. President Pfizer Worldwide R&D December 8th, 2016
2
Forward-looking Statements
• This presentation includes forward-looking statements about, among other things, development of Pfizer’s products and product candidates, including their potential benefits, expected clinical trial study starts and expected regulatory submissions and approvals that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these factors can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information.
• Factors that May Affect Future Results”, as well as in our subsequent reports on Form 8-K, all of which are filed with the US Securities and Exchange Commission (SEC) and available at www.sec.gov and www.pfizer.com.
• The forward-looking statements in this presentation speak only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements.
3 For presentation; not for distribution
Strong Track Record of Approvals Over the last 6 years >30 Phase 3 starts & >15 key approvals (10 NME’s)
Phase 1 36
94 Total
214 Discovery Projects
Phase 2 17
Phase 3 33
Registration 8
Discovery Projects
~50% biologics, biosimilars and vaccines
Robust Pipeline Positioned for Sustainable Productivity
Data as of November 1 2016
(Adult / CAPiTA)
Crisaborole* (*PDUFA 2017)
4 For presentation; not for distribution
2016 A Productive Year for Pfizer R&D Key Regulatory News Flow
APPR
OVA
LS
SUB
MIS
SIO
NS
Immuno Oncology Antibody Drug Conjugates
inotuzumab ALL
(US1/EU)
Mylotarg AML
(US/EU1)
avelumab Merkel Cell
(US/EU)
Cardiovascular
ertugliflozin T2D (US2)
1 Pending Acceptance; 2 Projected submission
Infant (CN)
Adv. BC (EU)
Rec. Adv. BC (US/EU)
QD MR (US)
ROS+ NSCLC (US/EU)
5 For presentation; not for distribution
ertugliflozin Diabetes
tofacitinib UC & PsA
avelumab Mono Multiple Cancers
avelumab + Inlyta®
Renal Cancer
C. Difficile Vaccine
JAK1 Atopic Dermatitis
Dopamine Modulation Parkinson’s
2016 A Productive Year for Pfizer R&D Key Clinical News Flow
PHASE 2 PHASE 3 PHASE 1
DAT
A R
EAD
OU
TS
STU
DY
STAR
TS
BACE, GSM Alzheimer's
Tyk2/JAK1 Psoriasis
P-cadherin Bi Fx Cancer
ACC, KHK NASH
glasdegib Leukemia
6 For presentation; not for distribution
EXTERNAL FOCUS AREAS SELECT 2016 ACTIVITIES
Enable Strategic Focus Areas via “Build & Buy” (GTx, I/O)
Access novel targets & breakthrough platforms
2016 A Productive Year for Pfizer R&D Leveraging the External Environment
Strengthen pipelines with highly differentiated, quality assets
7 For presentation; not for distribution
Delivering the Next Wave of Innovation (Potential Clinical Milestones by 2018)
ONCOLOGY RARE DISEASE
NEURO
I&I
CVMET VACCINES
Up to 10 Triplets & Doublets
Cancer Vaccine Triplet avelumab+41BB+OX40 avelumab+41BB+IDO
avelumab + ADC
3 Gene Therapy Assets
Hemophilia B DMD
Friedrich’s Ataxia
3 NASH Assets
ACC KHK
DGAT2
Up to 9 Clinical Vaccines
C.Diff RSV
Pneumo Nexgen
Up to 3 AD/PD Assets in Ph 2
Dopamine Modulation GSM BACE
~10 Ph 2 Selective Kinases
JAK1 JAK3
TYK2/JAK1
Q&A